Virtual Event | December 19, 2022

AAV & Ex Vivo Gene Lentiviral Therapy

Source: Cytiva

Douglas Sanders, Ph.D., VP Head of Translational Medicine at AVROBIO provides detailed examples of the diseases that are a better fit for AAV or ex vivo lentiviral gene therapy and why.

access the Virtual Event!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Cytiva